Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
[66] Zhang H et al. Expression of Vascular endotelial growth factor and its receptors KDR and Flt-1 in gastric<br />
cancer cells. World J Gastroenterol 8: 994-998, 200<br />
[67] Bates DO, Harper SJ. Regulation of vascular permeabilità by vascular endothelial growth factors.<br />
Vascular Pharmacol 39: 225- 237, 2002<br />
[68] Zachary I, Signaling mechanisms me<strong>di</strong>at-ing vascualar protective actions of Vascular endotelial growth<br />
factor. Am J Physiol Cell Physiol 280: C1375-C1386, 2001<br />
[69] Rajantie I, Ilmonen M, Alminaite A et al. Adult bone marrow-derived cells recruited, durino angiogenesis<br />
comprise precursors for periendo-thelial vascular mural cells. Blood 104: 2084-2086, 2004<br />
[70] Giampietro Gasparini, Raffaele Longo, Massimo Fanelli, et al, Combination of Antiangiogenetic therapy<br />
with Other Anticancer Therapies: Results, Challenges, and Open Questions JCO VOL 23; 6, feb 20, 2005<br />
[71] kim Kj, Li B, Houck K, Winer J, Ferrara N, The vascular endothelial growth factor proteins. Identification<br />
of biologically relevant regions by neutralizing monoclonal antibo<strong>di</strong>es. Growth Factors 1992; 71: 53-64<br />
[72] Lee CG et al. anti-VEGF treatment augments tumor ra<strong>di</strong>ation responce <strong>un</strong>der normoxic or hipoxic<br />
con<strong>di</strong>tions: Cancer Res 60, 5565-5570 (2000)<br />
[73] Hansen- Algenstaedt, N et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and<br />
cheotherapy. Cancer Res 60, 4556-4560 (2000)<br />
[74] Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, it<br />
receptor, and other angiogenic growth factors in human breast cancer. Cancer Res 1996; 56:2013-16<br />
[75] Heffelfinger SC, Miller MA, Yassin R, Gear R. Agiogenic growth factors in preinvasive breast cancer<br />
<strong>di</strong>sease. Clin Cancer Res 1999; 5:2867-76<br />
[76] Salvan P, Perhoniemi V, Tykka H, Maenpaa H; Joensouu H. Serum VEGF levels in women with benign<br />
breast tumor or breast cancer. Breast Cancer Res Treat 1999; 53:161-66<br />
[77] Jain RK. Normalizing tumour vasculature wiyh anti-angiogenic growth factor proteins: identification of<br />
biologically relevant regions by neutralizing monoclonal antibo<strong>di</strong>es. Growth Factors 1992; 71:53-64<br />
[78] Borgstrom P, Gold DP, Hillian KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in<br />
vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing<br />
antibody and doxorubicin.Anticancer Res 1999; 19: 4203-14<br />
[79] Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK; Shen J, Sledge GW Jr. The antiangiogenic<br />
property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular<br />
endothelial growth factor or 2-methoxyestra<strong>di</strong>ol but antagonized by endothelial growth factors. Cancer Res<br />
2001; 61: 3369-72<br />
[80] Gerber H, Ferrara N, Pharmacology and pharmacoynamics of bevacizumab as monotherapy or in<br />
combination with citotoxic therapy in preclinical stu<strong>di</strong>es. Cancer Res 2005; 65:671-80<br />
Maria Pittalis<br />
<strong>Valutazione</strong> <strong>di</strong> <strong>efficacia</strong> <strong>di</strong> <strong>un</strong> <strong>antiangiogenetico</strong> (<strong>Bevacizumab</strong>) associata a chemioterapia in pazienti con carcinoma<br />
della mammella metastatico<br />
Tesi <strong>di</strong> dottorato in scienze Biome<strong>di</strong>che-Epidemiologia molecolare dei tumori<br />
Università degli Stu<strong>di</strong> <strong>di</strong> Sassari<br />
86
Change language